Recombinant human endothelial cell growth factor
USRE37850E1 · kind E1 · reissue
0Cited by
16References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 28, 2000 |
| Grant date | Sep 17, 2002 |
| Priority date | — |
| Expiry date | Mar 28, 2020 |
Classification
- Technology area (CPC —)General
Abstract
Endothelial cell growth factor is achieved through the application of recombinant DNA technology to prepare cloning vehicles encoding the ECGF protein and procedures are disclosed for recovering ECGF protein essentially free of other proteins of human origin. The product is useful for, among other purposes, diagnostic applications and as potential in the treatment of damaged blood vessels or other endothelial cell-lined structures.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.